Haemonetics Corporation

Haemonetics Corporation, headquartered in Boston, Massachusetts, manufactures and supplies blood and plasma management medical devices, hemostasis analyzers, autotransfusion units, vascular closure systems, and related consumables to federal healthcare agencies as a prime contractor exclusively, competing on an open, full-and-open basis across military and civilian health systems with no set-aside participation. The company operates as a for-profit corporate entity and holds no SBA certifications; it maintains a parent structure with four named subsidiaries including 5D Information Management, Inc. and Arryx Inc.

Haemonetics' federal work concentrates on medical device supply and equipment maintenance across three primary capability areas. Blood management products include autotransfusion units (Cell Saver and NX series), hemostasis analyzers (TEG 5000, TEG 6 Platinum), and associated consumables such as blood bags, tubing sets, deglycerolization kits, nutrient additive solutions, and post-thaw reagents. Vascular closure systems—arterial and venous closure sheaths for cardiac electrophysiology procedures—enable same-day patient discharge. Maintenance services cover preventative maintenance, repair, and rebuild of blood management equipment at federal medical facilities. Representative work includes a $3.8 million single-award IDC with the Department of Veterans Affairs (contract 36C10G22D0019, through February 2027) supplying NX autotransfusion units and hemostasis analyzers across VA medical centers nationwide; a $99.8 thousand annual preventative maintenance contract with the Defense Health Agency at Brooke Army Medical Center for hemostasis analyzer systems through September 2027; and a $69 thousand firm fixed-price contract with VA Veterans Integrated Service Network 12 for haemolytic bags and blood-management consumables through September 2025.

Customer concentration reflects Haemonetics' position as a primary supplier to military and federal healthcare procurement channels. The Defense Health Agency leads by potential value at $16.2 million (42 awards), followed by the Department of the Navy Bureau of Medicine and Surgery ($8.3 million, 200 awards) and the Department of the Army Medical Command ($8.1 million, 106 awards). These three customers anchor 65% of combined potential value. The Defense Logistics Agency Troop Support Medical places the highest award count at 303 awards but carries lower per-order magnitude ($1.8 million combined), indicating routine consumables supply. The top five customer clusters by award count—DLA Troop Support Medical, Navy Bureau of Medicine and Surgery, Army Medical Command, VA VISN 19, and VA VISN 8—comprise 39% of all awards. Haemonetics serves 50 distinct federal agencies across the portfolio, with activity rooted in baseline supply relationships to established medical infrastructure.

The vendor holds a $3.8 million single-award IDC with VA (36C10G22D0019) and participates in four additional smaller parent vehicles: IDC N6264505D5021 with Navy (18 task orders, $766 thousand), BPA W81XWH12A0014 with Army (14 task orders, $66 thousand), BPA HT001418A0032 (7 task orders, $324 thousand), and IDC 36C10G19D0008 (2 task orders, $220 thousand). The VA IDC remains the primary vehicle anchoring Haemonetics' federal position; delivery orders under it typically run $22 thousand to $125 thousand per order. Overall, task-order activity from named vehicles accounts for approximately 44 awards carrying $1.6 million in combined potential value, leaving the majority of Haemonetics' footprint in direct purchase orders for discrete equipment and consumables.

Activity volume has declined modestly year over year: 13 awards in 2022, trailing to 7 in 2025 and 3 in the first half of 2026. Five awards (combined potential value $229 thousand) reach completion within the next twenty-four months, representing minimal recompete exposure relative to total portfolio size. The source data spans 1,796 total awards with $63 million combined potential value; Haemonetics' award count has grown substantially since registration in 2002, but recent-year velocity suggests maturation in established customer relationships rather than new-market penetration. The 1,796 award count reflects the vendor's distribution across medical supply networks where thousands of small consumables orders accumulate; mean order size is approximately $35 thousand, with significant orders ($100 thousand and above) concentrated in equipment maintenance contracts and larger VA delivery orders.

Haemonetics does not subcontract its federal work—the 100% prime award split across 1,796 awards confirms exclusive prime positioning with no sub-award footprint. The vendor competes without teaming relationships in the source data, positioning itself as a direct supplier of proprietary blood management equipment and consumables rather than as a systems integrator or managed-services provider. Medical and Surgical Instruments, Equipment, and Supplies (PSC category) account for 1,173 of the 1,796 awards, with secondary concentration in In Vitro Diagnostic Substances and Reagents (157 awards) and Laboratory Equipment and Supplies (117 awards). NAICS coding reflects manufacturing and distribution capability: Surgical and Medical Instrument Manufacturing (428 awards), Biological Product Manufacturing (117 awards), and Medical Equipment Merchant Wholesaling (93 awards) represent the primary classification footprint.